PD-L1 is critical for tumor cell escape from immune surveillance by inhibiting T cell function
via the PD-1 receptor. Accumulating evidence demonstrates that anti-PD-L1 monoclonal …

Abstract PD-1/PD-L1 immune checkpoint blockade therapy has been widely used for the
clinical treatment of cancer. However, recent clinical trials have shown that only a small …

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide, and
immune checkpoint blockade therapy provides an opportunity for improving the outcome of …

Macrophages (Mϕ) are prominent components of solid tumors and exhibit distinct
phenotypes in different microenvironments. We have recently found that tumors can alter the …

Colorectal cancer (CRC) is still considered as the third most frequent cancer in the world.
Microsatellite instability (MSI), inflammation, and microRNAs have been demonstrated as …

Background: The blockade of PD-1–PD-L1 pathway is emerging as an effective therapeutic
strategy for several advanced cancers. But the immune regulatory role of PD-1–PD-L1 …

The expression of PD-L1 in tumor cells is one of the main causes of tumor immune escape.
However, the exact mechanism for regulating PD-L1 expression in gastric cancer (GC) cells …

Myeloid-derived suppressor cells (MDSCs) have been demonstrated to suppress antitumor
immunity and induce resistance to PD-1/PD-L1 blockade immunotherapy in gastric and …

Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …

Abstract Background/Abstract: PD-L1 has been an important target of cancer
immunotherapy. We have showed that in human gastric cancer tissues, over-expression of …